DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $14.75.

A number of equities research analysts have recently commented on the company. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a research report on Thursday. HC Wainwright increased their price target on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 5th. Citigroup restated an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a research note on Thursday.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Stock Performance

Shares of NASDAQ:DBVT traded up $0.37 during trading on Friday, reaching $9.25. The company had a trading volume of 5,507 shares, compared to its average volume of 190,642. The firm's fifty day moving average is $9.24 and its 200 day moving average is $6.32. The firm has a market capitalization of $253.36 million, a PE ratio of -1.88 and a beta of -0.63. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 278.24% and a negative net margin of 3,249.99%. Equities analysts predict that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.